3,976
Views
7
CrossRef citations to date
0
Altmetric
Clinical Study

Risk factors for mortality in patients undergoing peritoneal dialysis: a systematic review and meta-analysis

, , &
Pages 743-753 | Received 07 Jan 2021, Accepted 09 Apr 2021, Published online: 29 Apr 2021

References

  • Tian Y, Xie X, Xiang S, et al. Risk factors and outcomes of early-onset peritonitis in Chinese peritoneal dialysis patients. Kidney Blood Press Res. 2017;42(6):1266–1276.
  • Collins AJ, Foley RN, Chavers B, et al. United States Renal Data System 2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis. 2012;59(1 Suppl 1):A7, e1–420.
  • Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. JASN. 2005;16(2):489–495.
  • Garcia-Lopez E, Carrero JJ, Suliman ME, et al. Risk factors for cardiovascular disease in patients undergoing peritoneal dialysis. Perit Dial Int. 2007;27(2_suppl):205–209.
  • Kalantar-Zadeh K, Kopple JD. Relative contributions of nutrition and inflammation to clinical outcome in dialysis patients. Am J Kidney Dis. 2001;38(6):1343–1350.
  • Pifer TB, McCullough KP, Port FK, et al. Mortality risk in hemodialysis patients and changes in nutritional indicators. DOPPS. Kidney Int. 2002;62(6):2238–2245.
  • Lee MJ, Shin DH, Kim SJ, et al. Progression of aortic arch calcification over 1 year is an independent predictor of mortality in incident peritoneal dialysis patients. PloS One. 2012;7(11):e48793.
  • Cai L, Yu J, Yu J, et al. Prognostic value of inflammation-based prognostic scores on outcome in patients undergoing continuous ambulatory peritoneal dialysis. BMC Nephrol. 2018;19(1):297.
  • Yang X, Soohoo M, Streja E, et al. Serum magnesium levels and hospitalization and mortality in incident peritoneal dialysis patients: a cohort study. Am J Kidney Dis. 2016;68(4):619–627.
  • Cai K, Luo Q, Dai Z, et al. Hypomagnesemia is associated with increased mortality among peritoneal dialysis patients. PloS One. 2016;11(3):e0152488.
  • Torlén K, Kalantar-Zadeh K, Molnar MZ, et al. Serum potassium and cause-specific mortality in a large peritoneal dialysis cohort. CJASN. 2012;7(8):1272–1284.
  • Xu Q, Xu F, Fan L, et al. Serum potassium levels and its variability in incident peritoneal dialysis patients: associations with mortality. PloS One. 2014;9(1):e86750.
  • Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
  • Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ (Clin Res ed). 2003;327(7414):557–560.
  • Ye H, Zhou Q, Fan L, et al. The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients. BMC Nephrol. 2017;18(1):186.
  • Xiang S, Zhang X, Xie X, et al. High serum uric acid level is a mortality risk factor in peritoneal dialysis patients: a retrospective cohort study. Nutr Metabol. 2019;16:52.
  • Xue Y, Xu B, Su C, et al. Cardiorenal syndrome in incident peritoneal dialysis patients: what is its effect on patients’ outcomes? PLoS One. 2019;14(6):e0218082.
  • Hwang SD, Lee JH, Jhee JH, et al. Impact of body mass index on survival in patients undergoing peritoneal dialysis: Analysis of data from the Insan Memorial End-Stage Renal Disease Registry of Korea (1985–2014). Kidney Res Clin Pract. 2019;38(2):239–249.
  • Lai KJ, Kor CT, Hsieh YP. An inverse relationship between hyperuricemia and mortality in patients undergoing continuous ambulatory peritoneal dialysis. JCM. 2018;7(11):416.
  • Jung HY, Kim SH, Jang HM, et al. Individualized prediction of mortality using multiple inflammatory markers in patients on dialysis. PloS One. 2018;13(3):e0193511.
  • Liu Y, Zhu JG, Cheng BC, et al. An association between time-varying serum alkaline phosphatase concentrations and mortality rate in patients undergoing peritoneal dialysis: a five-year cohort study. Sci Rep. 2017;7(1):43314.
  • Rhee CM, Molnar MZ, Lau WL, et al. Comparative mortality-predictability using alkaline phosphatase and parathyroid hormone in patients on peritoneal dialysis and hemodialysis. Perit Dial Int. 2014;34(7):732–748.
  • Liu X, Guo Q, Feng X, et al. Alkaline phosphatase and mortality in patients on peritoneal dialysis. CJASN. 2014;9(4):771–778.
  • Li W, Xiong L, Fan L, et al. Association of baseline, longitudinal serum high-sensitive C-reactive protein and its change with mortality in peritoneal dialysis patients. BMC Nephrol. 2017;18(1):211.
  • Lee S, Kang E, Yoo KD, et al. Lower serum potassium associated with increased mortality in dialysis patients: a nationwide prospective observational cohort study in Korea. PloS One. 2017;12(3):e0171842.
  • Kim YK, Kim SH, Kim HW, et al. The association between body mass index and mortality on peritoneal dialysis: a prospective cohort study. Perit Dial Int. 2014;34(4):383–389.
  • Prasad N, Sinha A, Gupta A, et al. Effect of body mass index on outcomes of peritoneal dialysis patients in India. Perit Dial Int. 2014;34(4):399–408.
  • Tian Y, Xie X, Xiang S, et al. Risk factors and outcomes of high peritonitis rate in continuous ambulatory peritoneal dialysis patients: a retrospective study. Medicine. 2016;95(49):e5569.
  • Feng S, Wang Y, Qiu B, et al. Impact of early-onset peritonitis on mortality and technique survival in peritoneal dialysis patients. SpringerPlus. 2016;5(1):1676.
  • Liu X, Huang R, Wu H, et al. Patient characteristics and risk factors of early and late death in incident peritoneal dialysis patients. Sci Rep. 2016;6(1):32359.
  • Wu X, Yang X, Liu X, et al. Patient survival and technique failure in continuous ambulatory peritoneal dialysis patients with prior stroke. Perit Dial Int. 2016;36(3):308–314.
  • Xiong L, Cao S, Xu F, et al. Association of body mass index and body mass index change with mortality in incident peritoneal dialysis patients. Nutrients. 2015;7(10):8444–8455.
  • Dong J, Han QF, Zhu TY, Ren YP, et al. The associations of uric acid, cardiovascular and all-cause mortality in peritoneal dialysis patients. PloS One. 2014;9(1):e82342.
  • Wang AY, Woo J, Lam CW, et al. Is a single time point C-reactive protein predictive of outcome in peritoneal dialysis patients? Journal of the American Society of Nephrology: JASN. 2003;14(7):1871–1879.
  • Guan JC, Bian W, Zhang XH, et al. Influence of peritoneal transport characteristics on nutritional status and clinical outcome in Chinese diabetic nephropathy patients on peritoneal dialysis. Chinese Medical Journal. 2015;128(7):859–864.
  • Rumpsfeld M, McDonald SP, Johnson DW. Higher peritoneal transport status is associated with higher mortality and technique failure in the Australian and New Zealand peritoneal dialysis patient populations. JASN. 2006;17(1):271–278.
  • Shah S, Leonard AC, Thakar CV. Functional status, pre-dialysis health and clinical outcomes among elderly dialysis patients. BMC Nephrol. 2018;19(1):100.
  • Yang ZK, Han QF, Zhu TY, et al. The associations between the family education and mortality of patients on peritoneal dialysis. PloS One. 2014;9(5):e95894.
  • Yang CW, Tzeng NS, Yin YJ, et al. Angiotensin receptor blockers decrease the risk of major adverse cardiovascular events in patients with end-stage renal disease on maintenance dialysis: a nationwide matched-cohort study. PloS One. 2015;10(10):e0140633.
  • Duong U, Mehrotra R, Molnar MZ, et al. Glycemic control and survival in peritoneal dialysis patients with diabetes mellitus. CJASN. 2011;6(5):1041–1048.
  • Abe M, Hamano T, Hoshino J. Glycemic control and survival in peritoneal dialysis patients with diabetes: a 2-year nationwide cohort study. Sci Rep. 2019;9(1):3320.
  • Kalantar-Zadeh K, Abbott KC, Salahudeen AK, et al. Survival advantages of obesity in dialysis patients. Am J Clin Nutr. 2005;81(3):543–554.
  • Kiran VR, Zhu TY, Yip T, et al. Body mass index and mortality risk in Asian peritoneal dialysis patients in Hong Kong-impact of diabetes and cardiovascular disease status. Perit Dial Int. 2014;34(4):390–398.
  • Johnson DW, Mudge DW, Sturtevant JM, et al. Predictors of decline of residual renal function in new peritoneal dialysis patients. Perit Dial Int. 2003;23(3):276–283.
  • Yoon JW, Gollapudi S, Pahl MV, et al. Naive and central memory T-cell lymphopenia in end-stage renal disease. Kidney Int. 2006;70(2):371–376.
  • Karbowska A, Boratynska M, Kusztal M, et al. Hyperuricemia is a mediator of endothelial dysfunction and inflammation in renal allograft recipients. Transpl Proc. 2009;41(8):3052–3055.
  • Park JT, Kim DK, Chang TI, et al. Uric acid is associated with the rate of residual renal function decline in peritoneal dialysis patients. Nephrology, dialysis, transplantation: official publication of the European Dialysis and Transplant Association. Eur Renal Assoc. 2009;24(11):3520–3525.